Helixon

Helixon (华深智药) is an AI-driven biotechnology company developing next-generation antibody therapies, operating internationally through its overseas entity Earendil Labs . Founded by Peng Jian in June 2021, the company built an AI-powered scientific computing platform integrating high-throughput biological experimentation to accelerate large-molecule drug discovery . It gained early recognition for OmegaFold, an algorithm achieving protein 3D structure prediction from single sequences .

The company has since advanced to clinical-stage pipelines and major pharmaceutical partnerships. In April 2025, Earendil Labs signed a global exclusive licensing deal with Sanofi for two first-in-class bispecific antibodies targeting autoimmune and inflammatory bowel diseases . In March 2026, it raised $787 million in multiple financing rounds, which 高榕创投 reported as a new global record for biotech fundraising that year . 5Y Capital, which led Helixon's Series A in 2022 and has backed it through successive rounds, described the firm as one of its most resolute bets in AI for Science, citing the team's rare density of cross-disciplinary talent and its closed loop of algorithm-experimental validation .